Released on = August 21, 2006, 6:38 am

Press Release Author = Gentris Corporation

Industry = Pharmaceuticals

Press Release Summary = Companies establish Japan's first GLP-compliant
pharmacogenomics laboratory

Press Release Body = Research Triangle Park, North Carolina, USA - August 21st 2006
- Gentris Corporation (Gentris), a leading global provider of applied clinical
pharmacogenomic services and diagnostic product solutions, today announced the
company has partnered with FALCO biosystems Ltd. (FALCO), one of the largest
publicly-traded medical testing laboratories in Japan. The exclusive ten-year
licensing agreement marks the establishment of Japan's first Good Laboratory
Practice (GLP)-compliant pharmacogenomics laboratory, moving Japan into the era of
personalized medicine.

The partnership, to be called "Gentris Japan", will offer pharmacogenomics services
to the pharmaceutical industry in Japan, the second-largest pharmaceutical market in
the world after the United States.

The partnership is a natural, strategic move for both Gentris and FALCO as global
pharmaceutical companies in Japan increasingly look to effectively integrate
pharmacogenomics into their drug development programs. Gentris already serves a
large client base of pharmaceutical companies in Japan and therefore has developed a
strong reputation and brand within the market. As the country's first GLP-compliant
pharmacogenomics laboratory, Gentris Japan will have a clear competitive advantage
in meeting the high standards of the global pharmaceutical industry.

"It is evident that pharmacogenomics is going to be as important to drug
development, and ultimately the public, in Japan as it is in the United States and
Europe," commented Gentris CEO Michael Murphy. "For several drugs routinely
prescribed in Japan, research has identified clear relationships between individual
genetic differences and how these drugs are metabolized. Gentris Japan will work to
ensure that people receive safer and more effective medications, at the appropriate
dosage, based on these individual genetic variations."

"By partnering with FALCO, a Japanese leader in applications of molecular biology
with facilities throughout the country, we are strategically positioned to better
serve our current clients while at the same time developing new relationships with
global pharmaceutical companies in the market," Murphy continued.

"Our mission is to help society achieve higher standards of living and health
through information, technology and services," said FALCO Chairman and President
Hiroharu Akazawa. "Partnering with Gentris to introduce the first GLP-compliant
pharmacogenomics laboratory in Japan is a great step in the advancement of
personalized medicine. Gentris' superior standards of practice and longstanding
leadership in the field of pharmacogenomics make the company an ideal partner for
FALCO. We look forward to working together to bring safer and more effective drugs
to the Japanese public."

###

About Gentris Corporation
Gentris Corporation is a leading global provider of applied clinical pharmacogenomic
services and diagnostic product solutions. As pioneers in the field of
pharmacogenomics, Gentris helps pharmaceutical companies and clinical research
organizations effectively integrate pharmacogenomics into their drug development
programs to deliver safer, more effective compounds to the market sooner. Gentris is
developing validated reference controls and diagnostic test kits that will bring the
promise of personalized medicine to physicians and patients, which will enhance
patient management, improve patients\' response to therapy and revolutionize medicine
through pharmacogenomics. For additional information, please visit
http://www.gentris.com




Web Site = http://

Contact Details = Jonathan Jordan
919Marketing/919.557.7890
press@gentris.com